Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma
Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4 million milestone payment...
September 2025
FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements
The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration...
MSD scrapes £1 billion UK expansion, shifts life‑science research to the US
US‑based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the cancellation of...
FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration
Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...
NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials
The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...
Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus
China‑based Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...
GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B
China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...
Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...
YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...
Novartis Secures Tabrecta Approval in China for METex14 NSCLC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib...
China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls
At a State Council Information Office press conference, Deputy Director of the National Health Commission...
China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings
The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...
China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach
The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...
TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...
Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access
Innovent Biologics Inc. (HKG: 1801) announced a strategic cooperation agreement with Cowell Health. The partnership is...
Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar
China‑based Chongqing Taiji Industry (Group) Co., Ltd. (Taiji Group, SHA: 600129) announced that its semaglutide...
Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...
Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation
China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...
Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development
China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...
Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced that its operating subsidiary,...